Back to mobile site

Argus on Zimmer Biomet (ZBH): 'this as an attractive valuation'

March 30, 2026 7:27 AM EDT Send to a Friend
Argus analyst David Toung reiterated a Buy rating and $125.00 price target on Zimmer Biomet (NYSE: ZBH).The analyst comments "Restructuring ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login